Advertisement

Pharmacological Effects of MDMA in Man

  • Enno Freye
Chapter

Abstract

Ecstasy or MDMA in its pure form is a white crystalline powder. It is usually seen in capsule form, in pressed pills (Fig. 4), or as loose powder. Common routes of administration are swallowing or snorting, although it can be smoked or injected as well. MDMA in the US and Europe is on Schedule I of controlled substances, and it is illegal to manufacture, possess, or sell it in the United States or other countries, who have similar laws.

Usual doses of MDMA in humans range from around 80–60 mg orally, while lower doses (40–60 mg) are used to assist meditation, and in psychotherapy. Subjective effects peak between 90 min and 2 h after ingestion of MDMA and return to baseline approximately 4 h after ingestion. A benchmark standard dose is often considered to be 2 mg of MDMA per kg of body weight, though response to the drug is not strictly proportional to body weight. When MDMA is taken orally, the effects manifest about 30–45 min later; snorting, smoking or injecting produces a much quicker onset (Table 1). The primary effects usually reach a plateau 1 h after taking the dose. It stays there for some 2 h, then start tapering gradually being over by four to 6 h. The psychological effects largely dissipate in 3 h with the exception of some residual sympathomimetic effects, which may last up to 5 h. Secondary effects (afterglow) may be felt for days, and tertiary psychological effects (e.g. improved outlook) may last indefinitely [3].

Keywords

Ecstasy User Mdma User Emotional Closeness MDMA Administration Distribution Volume Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 3.
    Shulgin A, Nichols D. Characterization of three new psychomimetics. In: Stillmann R, Wilette R, editors. The Psychopharmacology of Halluzinogens. New York: Pergamon; 1978. pp. 74–82.Google Scholar
  2. 4.
    Shulgin A. Pihkal: a chemical love story. Berkeley: Transform Press; 1995.Google Scholar
  3. 15.
    State RC, Grob CS, Poland RE, editors. Psychobiologic Effects of 3,4-Methylenedioxy­methamphetamine in Humans: A Pilot Study (Poster). MDMA/Ecstasy Research: Advances, Challenges and Future Directions; 2001; Bethesda, MD: US Goverment.Google Scholar
  4. 20.
    Liechti ME, Geyer MA, Hell ID, Vollenweider FX. Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology. 2001;24:240–252.PubMedCrossRefGoogle Scholar
  5. 21.
    Liester MB, Grob CS, Bravo GL, Walsh RN. Phenomenology and sequelae of 3,4-methylenedioxy-methamphetamine use. J Nerv Ment Dis. 1992;180:345–352.PubMedCrossRefGoogle Scholar
  6. 22.
    Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals: neurochemical and anatomical evidence. Science. 1985;229:986–988.PubMedCrossRefGoogle Scholar
  7. 23.
    Lamers GTJ, Ramaekers JG, Muntjewerff ND, Sikkema KL, Riedel WJ, Samyn N, et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharm. 2003;17:379–387.CrossRefGoogle Scholar
  8. 24.
    Mathias R. “Ecstasy” damages the brain and impairs memory in humans. NIDA Notes. 1999;14:10–15.Google Scholar
  9. 25.
    Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine: a double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:969–972.PubMedGoogle Scholar
  10. 26.
    Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res. 1996;73:103–107.PubMedCrossRefGoogle Scholar
  11. 27.
    Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96:678–685.PubMedCrossRefGoogle Scholar
  12. 28.
    Davis WM, Hatoum HT, Waters IW. Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse. Alcohol Drug Res.. 1987;7:123–134.PubMedGoogle Scholar
  13. 29.
    Peroutka SJ, Pascoe N, Faull KF. Monoamine metabolites in the cerebrospinal fluid of recreational users of 3 4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Res Commun Subst Abuse. 1987;8:125–138.Google Scholar
  14. 30.
    Ricaurte GA, Forno LS, Wilson MA, DeLanney L, Irwin I, Molliver ME, et al. (±)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988;260:51–55.PubMedCrossRefGoogle Scholar
  15. 31.
    Ricaurte GA, Matello AL, Katz JL, Martello MB. Long lasting effects of (±)-3,4-methylenedioxyamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther. 1992;261:616–622.PubMedGoogle Scholar
  16. 32.
    Reneman L, Booij J, den Heeten GJ, van den Brin W. Effects of MDMA (ecstasy) use and abstention on serotonin neurons. Lancet. 2002;359:1617–1618.CrossRefGoogle Scholar
  17. 33.
    Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“Ecstasy”). Science. 2002;297:2260–2263.PubMedCrossRefGoogle Scholar
  18. 34.
    Grob CS. Decontructing ecstasy: the epolitics of MDMA research. Addict Res. 2000;6:549–588.CrossRefGoogle Scholar
  19. 35.
    Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma J, Gunning B, et al. Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study - preliminary report. Psychopharmacology. 2002;159:335–340.PubMedCrossRefGoogle Scholar
  20. 36.
    Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of parkinson disease. PLoS Biol. 2005;3:e271.PubMedCrossRefGoogle Scholar
  21. 37.
    Morris K. Concern over research reawakens ecstasy neurotoxicity debate. Lancet. 2003;2:650.CrossRefGoogle Scholar
  22. 38.
    Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, et al. Long-term effects of “Ecstasy” use on serotonin transporters of the brain investigated by PET. J Nucl Med. 2003;44:375–384.PubMedGoogle Scholar
  23. 39.
    Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with MDMA seven years previously: factors influencing abnormal recovery. J Neurosci. 1999;19:5096–5107.PubMedGoogle Scholar
  24. 40.
    Hiramatsu M, Kumagai Y, Unger SE, Cho AK. Metabolism of methylenedioxymethamphetamine: formation of dihydroxy-methamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther. 1990;25:521–527.Google Scholar
  25. 41.
    Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine (“Ecstasy”) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994;47:1151–1156.PubMedCrossRefGoogle Scholar
  26. 42.
    Zhao ZY, Castagnoli NJ, Ricaurte GA, Steele T, Martello M. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)-methamphetamine]. Chem Res Toxocol. 1992;5:89–94.CrossRefGoogle Scholar
  27. 43.
    Lim HK, Foltz RL. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol. 1988;1:370–378.PubMedCrossRefGoogle Scholar
  28. 44.
    Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology. 1086;25:559–561.CrossRefGoogle Scholar
  29. 45.
    Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radical Biol Med. 1992;13:391–405.CrossRefGoogle Scholar
  30. 46.
    Wagner G, Carelli R, Jarvis M. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Path Pharm. 1985;47:221–228.PubMedGoogle Scholar
  31. 47.
    Leibovitz B. Phenethylamines, free radicals, and antioxidants. Multidiscip Ass Psychodel Stud. 1993;4:1–3.Google Scholar
  32. 48.
    McCann UD, Ricaurte CA. Reinforcing subjective effects of (±) 3,4-methylenedioxymetha­niphetamine (“ecstasy”) may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharm. 1993;13:214–217.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  1. 1.Heinrich-Heine-UniversityDüsseldorfGermany

Personalised recommendations